CN108601830B - 双特异性抗体平台 - Google Patents

双特异性抗体平台 Download PDF

Info

Publication number
CN108601830B
CN108601830B CN201680081272.6A CN201680081272A CN108601830B CN 108601830 B CN108601830 B CN 108601830B CN 201680081272 A CN201680081272 A CN 201680081272A CN 108601830 B CN108601830 B CN 108601830B
Authority
CN
China
Prior art keywords
amino acid
polypeptide
seq
acid sequence
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680081272.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN108601830A (zh
Inventor
M.普瑞尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CN108601830A publication Critical patent/CN108601830A/zh
Application granted granted Critical
Publication of CN108601830B publication Critical patent/CN108601830B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/66—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a swap of domains, e.g. CH3-CH2, VH-CL or VL-CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201680081272.6A 2015-12-18 2016-12-15 双特异性抗体平台 Active CN108601830B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562269664P 2015-12-18 2015-12-18
US62/269,664 2015-12-18
PCT/US2016/066865 WO2017106462A1 (en) 2015-12-18 2016-12-15 Bispecific antibody platform

Publications (2)

Publication Number Publication Date
CN108601830A CN108601830A (zh) 2018-09-28
CN108601830B true CN108601830B (zh) 2023-02-03

Family

ID=57681809

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680081272.6A Active CN108601830B (zh) 2015-12-18 2016-12-15 双特异性抗体平台

Country Status (9)

Country Link
US (1) US11447575B2 (2)
EP (1) EP3389710A1 (2)
JP (2) JP7138046B2 (2)
KR (1) KR20180100136A (2)
CN (1) CN108601830B (2)
AU (1) AU2016370821A1 (2)
CA (1) CA3008840A1 (2)
MA (1) MA44054A (2)
WO (1) WO2017106462A1 (2)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201901557XA (en) * 2016-08-26 2019-03-28 Sanofi Sa Multispecific antibodies facilitating selective light chain pairing
EP3661555B1 (en) 2017-08-01 2025-04-16 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
CN110028588A (zh) * 2018-01-11 2019-07-19 上海细胞治疗研究院 抗原-Fc融合蛋白及其检测阳性CAR-T细胞的应用
CN113508135A (zh) 2018-10-29 2021-10-15 比奥根Ma公司 增强血脑屏障转运的人源化和稳定化的fc5变体
CA3120800A1 (en) 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager
WO2020159918A2 (en) 2019-01-28 2020-08-06 Ab Therapeutics, Inc. Bispecific antibodies and uses thereof
US20220227827A1 (en) * 2019-03-25 2022-07-21 Dingfu Biotarget Co., Ltd. Proteinaceous heterodimer and use thereof
CN114302893B (zh) * 2019-08-15 2025-01-28 瑞泽恩制药公司 用于细胞靶向的多特异性抗原结合分子及其用途
KR20220050166A (ko) * 2019-08-23 2022-04-22 아이쥐엠 바이오사이언스 인코포레이티드 Igm 글리코변이체
JP2022550316A (ja) * 2019-09-25 2022-12-01 ウニヴェルズィテート シュトゥットガルト 修飾ｅｈｄ２ドメインを含む結合モジュール
CA3164979A1 (en) * 2020-01-09 2021-07-15 Jiangsu Hengrui Medicine Co., Ltd. New polypeptide complex
CN113307879A (zh) * 2020-02-27 2021-08-27 启愈生物技术(上海)有限公司 一种taa/ctla-4/il15三功能融合蛋白及其应用
CN113563473A (zh) * 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
IL301926A (en) * 2020-11-06 2023-06-01 Amgen Inc Antigen binding domain with reduced clipping rate
CA3219388A1 (en) * 2021-05-14 2022-11-17 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Antigen-binding molecule
WO2023010060A2 (en) 2021-07-27 2023-02-02 Novab, Inc. Engineered vlrb antibodies with immune effector functions
KR20250075665A (ko) * 2022-09-28 2025-05-28 드렌 바이오, 인크. 다중특이적 항체 및 이의 사용 방법
WO2025042806A2 (en) 2023-08-21 2025-02-27 Modernatx, Inc. C-met binding antibodies, nucleic acids encoding same, and methods of use
WO2026044055A1 (en) 2024-08-23 2026-02-26 Modernatx, Inc. Muc16 binding molecules, nucleic acids encoding same, and methods of use
WO2026075820A1 (en) 2024-10-03 2026-04-09 Modernatx, Inc. 4-1bb binding molecules, nucleic acids encoding same, and methods of use
CN121148519B (zh) * 2025-11-18 2026-02-13 西北农林科技大学 基于计算模拟辅助的双特异性抗体分子设计与优化方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903404A (zh) * 2007-12-21 2010-12-01 霍夫曼-拉罗奇有限公司 二价双特异性抗体
WO2013156148A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart THE IgM AND IgE HEAVY CHAIN DOMAIN 2 AS COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY
CN104379604A (zh) * 2012-05-24 2015-02-25 弗·哈夫曼-拉罗切有限公司 多特异性抗体
WO2015058048A1 (en) * 2013-10-18 2015-04-23 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5768147B2 (ja) * 2011-02-28 2015-08-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 一価抗原結合タンパク質
US9738707B2 (en) * 2011-07-15 2017-08-22 Biogen Ma Inc. Heterodimeric Fc regions, binding molecules comprising same, and methods relating thereto
ES2935274T3 (es) * 2014-12-05 2023-03-03 Merck Patent Gmbh Anticuerpo con intercambio de dominios
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
SG11201901557XA (en) * 2016-08-26 2019-03-28 Sanofi Sa Multispecific antibodies facilitating selective light chain pairing
CA3120800A1 (en) * 2018-12-17 2020-06-25 Revitope Limited Twin immune cell engager

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101903404A (zh) * 2007-12-21 2010-12-01 霍夫曼-拉罗奇有限公司 二价双特异性抗体
WO2013156148A1 (en) * 2012-04-16 2013-10-24 Universität Stuttgart THE IgM AND IgE HEAVY CHAIN DOMAIN 2 AS COVALENTLY LINKED HOMODIMERIZATION MODULES FOR THE GENERATION OF FUSION PROTEINS WITH DUAL SPECIFICITY
CN104379604A (zh) * 2012-05-24 2015-02-25 弗·哈夫曼-拉罗切有限公司 多特异性抗体
WO2015058048A1 (en) * 2013-10-18 2015-04-23 Regeneron Pharmaceuticals, Inc. Methods and compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Tetravalent Antibody–scTRAIL Fusion Proteins with Improved Properties;Oliver Seifert等;《Molecular Cancer Therapeutics》;20140131;第13卷(第1期);第101-111页 *
The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity;Oliver Seifert等;《Protein Engineering, Design & Selection》;20120917;第25卷(第10期);第603-612页 *

Also Published As

Publication number Publication date
JP2019502694A (ja) 2019-01-31
MA44054A (fr) 2018-10-24
US11447575B2 (en) 2022-09-20
EP3389710A1 (en) 2018-10-24
KR20180100136A (ko) 2018-09-07
CA3008840A1 (en) 2017-06-22
JP2021121642A (ja) 2021-08-26
WO2017106462A1 (en) 2017-06-22
JP7138046B2 (ja) 2022-09-15
US20190048098A1 (en) 2019-02-14
AU2016370821A1 (en) 2018-07-12
CN108601830A (zh) 2018-09-28

Similar Documents

Publication Publication Date Title
CN108601830B (zh) 双特异性抗体平台
JP7788113B2 (ja) Ｃｈ３ドメインに基づくヘテロダイマー分子、その調製方法及び用途
AU2015357053B2 (en) Domain-exchanged antibody
EP2927321B1 (en) Ch3 domain variant pair inducing formation of heterodimer of heavy chain constant region of antibody at high efficiency, method for preparing same, and use thereof
DK2235064T3 (en) A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
JP2019528051A (ja) 修飾抗原結合Ｆａｂ断片及びこれを含む抗原結合分子
CN110520445B (zh) 抗pd-l1/抗pd-1天然抗体结构样异源二聚体形式双特异抗体及其制备
KR20250152665A (ko) Ｆc-함유 폴리펩타이드의 안정화
EP4303231A1 (en) Bispecific antibody
EP3728328A1 (en) Bispecific antigen binding construct
TW202311295A (zh) 一種抗原結合分子
WO2022125986A1 (en) Orthogonal mutations for heterodimerization
JP2025505611A (ja) Ｐｓｍａとｃｄ３に特異的に結合する抗原結合分子及びその医薬的使用
WO2023038548A1 (ru) Биспецифическое антитело, содержащее гетеродимер на основе мнс белков
JPWO2022166728A5 (2)
EA051713B1 (ru) Биспецифическое антитело
CA3243665A1 (en) Antigen-binding molecule specifically binding to psma and cd3, and pharmaceutical use thereof
TW202528360A (zh) 藉由重組反應製備異源多聚體的方法
WO2026067827A1 (zh) 一种制备异源多聚体的方法及应用
CN117916259A (zh) 特异性结合cgrp和pacap的抗原结合分子及其医药用途
HK40004713B (zh) 抗pd‐1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant